Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Topical Ruxolitinib Evaluation in Immune-related Vitiligo-like Depigmentation (TRuE-VLD)

20 de julho de 2026 atualizado por: Lara Maul-Duwendag, University of Zurich

Topical Ruxolitinib for the Treatment of Immune-related Vitiligo-like Depigmentation: A Prospective, Multicentre Study of a Topical JAK-inhibitor

White spot disease is a common side effect on the skin in the context of cancer treatments with immunotherapies. There is no standard therapy yet for white spot caused by cancer therapies. There is already research in humans on the treatment of white spot disease. Previous human studies with ruxolitinib cream have shown that approximately 30% of patients with white spot disease have achieved a 75% improvement (re-pigmentation) of their affected areas after 24 weeks and approximately 50% of patients have achieved a 75% improvement after 52 weeks. It is also know that a 50% improvement was observed in over 50% of patients after 24 weeks and a 90% improvement in over 15% of patients. However, these studies to date have not included patients with white spot disease caused by cancer therapy. Therefore, we do not know how well the cream works in this situation. In this study, the investigators are therefore examining whether the investigational substance ruxolitinib is effective and well tolerated in white spot disease caused by cancer therapy. The test substance has not yet been approved in Switzerland. Only once the efficacy of the investigational substance ruxolitinib has been scientifically investigated and proven can it be approved in Switzerland and used to treat white spot disease caused by cancer therapy.

Visão geral do estudo

Status

Ativo, não recrutando

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

34

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Zurich, Suíça, 8058
        • Universitätsspital Zürich

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

Adult patients eligible for this inclusion in this study have to fulfil all the following criteria:

  • Age 18 years
  • Written informed consent of the patient
  • Sufficient fluency in German language skills to complete all questionnaires of the study without external assistance
  • Treatment-related, immune-related vitiligo-like depigmentation of at least 5% body surface area of one region (face or one upper or lower extremity or front or back side of the trunk)
  • Female participants must use effective contraceptives, either: An ovulation-inhibiting method (e.g., pill, injectable, implant, patch, or vaginal ring) or an intrauterine device (IUD). Contraception should extend one week post-study. If pregnancy occurs during or within one week after the study, participants should notify the overseeing physician immediately.
  • During participation in the study and up to one week afterwards, male participants may only have sexual intercourse with condoms. Female partners of male participants must use a highly effective contraceptive method during the partner's participation in the study and for up to 1 week afterwards

Exclusion Criteria:

Patients fulfilling any of the following criteria are not eligible for the inclusion in this study:

  • Acute psychiatric illness (except mild to moderate depression)
  • Contraindications to ruxolitinib, e.g. known hypersensitivity or allergy
  • Use of topical glucocorticosteroids, topical calcineurin inhibitors, UV light therapy, therapeutic biologics, other JAK inhibitors or potent immunosuppressants such as azathioprine or cyclosporine are not allowed during the study period (no wash out period required).
  • Women who are pregnant or breast feeding
  • Intention to become pregnant during the course of the study
  • Known or suspected non-compliance, drug or alcohol abuse.
  • Patients with an active, serious infection, including localized infections.
  • Inability to follow the procedures of the study due to language problems, psychological disorders, dementia of the participant.
  • Participation in another trial with topical or oral ruxolitinib within the 30 days preceding and during the present study.
  • Simultaneously participation in clinical trials with intervention with a drug other than ruxolitinib (except registry studies)
  • Previous enrolment into the current study.
  • Enrolment of the investigator, his/her family members, employees and other dependent persons.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Topical ruxolitinib
This study will be performed as one-arm with no comparator.
Ruxolitinib cream 1.5% will be applied topically twice daily over 52 weeks in patients with immune-related vitiligo-like depigmentation.
Outros nomes:
  • Topical Ruxolitinib (OPZELURA)

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Proportion of patients achieving a Facial vitiligo scoring index of 75% (F-VASI75) at week 24
Prazo: week 24
The F-VASI is a measure for assessing the success of treatment. The F-VASI assesses the percentage of repigmentation on the face. Achieving an F-VASI of 75% means that a 75% improvement in facial repigmentation has been achieved. This is determined by visually assessing the percentage of skin area that has returned to its normal color as a result of the treatment. The F-VASI is made up of the degree of depigmentation in percent and the size of the affected skin surface in percent. Percentage of depigmentation (0% = no depigmentation present, 100% = completely depigmented skin) is multiplied by the size of the affected skin area on the face in percent.
week 24

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Proportion of patients achieving a F-VASI of 25%, 50% and 90% (F-VASI25/50/90)
Prazo: week 24 and 52
The F-VASI assesses the percentage of repigmentation on the face. Achieving an F-VASI of 50% means that a 50% improvement in facial repigmentation has been achieved. The same applies to an F-VASI of 25% or 90%; this corresponds to 25% respectively 90% repigmentation. The F-VASI is made up of the degree of depigmentation in percent and the size of the affected skin surface in percent. Percentage of depigmentation (0% = no depigmentation present, 100% = completely depigmented skin) is multiplied by the size of the affected skin area on the face in percent.
week 24 and 52
Proportion of patients achieving a F-VASI 75 only at week 52
Prazo: week 52
The F-VASI assesses the percentage of repigmentation on the face. Achieving an F-VASI of 75% means that a 75% improvement in facial repigmentation has been achieved. The F-VASI is made up of the degree of depigmentation in percent and the size of the affected skin surface in percent. Percentage of depigmentation (0% = no depigmentation present, 100% = completely depigmented skin) is multiplied by the size of the affected skin area on the face in percent.
week 52
Proportion of patients achieving a Total Vitiligo Area Scoring Index of 25%, 50%, 75% and 90% (T-VASI25/50/75/90)
Prazo: week 24 and 52
T-VASI is a measure used to evaluate the success of vitiligo treatment over the entire body. A T-VASI of for instance 75% means that a 75% improvement in repigmentation of the entire skin of the body has been achieved. The T-VASI is calculated by estimating and weighting the area of depigmented skin and the degree of repigmentation. Percentage of depigmentation (0% = no depigmentation present, 100% = completely depigmented skin) is multiplied by the affected body surface area in percent. The unit of "Proportion of patients achieving a Total Vitiligo Area Scoring Index of 25%, 50%, 75% and 90% (T-VASI25/50/75/90)" is a percentage. It is looked at what percentage of participants have achieved an improvement in their T-VASI score. It is looked at how many participants have achieved a 25% improvement, how many a 50% improvement, how many a 75% improvement and how many a 90% improvement in their T-VASI score.
week 24 and 52
Proportion of patients achieving 4 points ("a lot less noticeable") or 5 points ("no longer noticeable") in the Vitiligo Noticeability Scale (VNS)
Prazo: week 24 and 52
The VNS is an assessment tool developed to measure the visibility, conspicuousness and appearance of vitiligo spots. The score has a scale from one to five. One means more noticeable, five means no noticeability/visibility.
week 24 and 52
Percentage change from baseline in the Facial Body Surface Area (F-BSA) and Total Body Surface Area (T-BSA)
Prazo: week 24 and 52
Calculation of the affected body surface area as a percentage. Once the affected surface on the face and once the affected surface on the entire integument.
week 24 and 52
Percentage change from baseline in the Facial Physician's Global Vitiligo Assessment (F-PhGVA) and Total Physician's Global Vitiligo Assessment (T-PhGVA)
Prazo: week 24 and 52

The F-PhGVA is an assessment tool used by physicians to evaluate the severity of facial vitiligo. It is based on a global assessment by the treating physician and takes into account various aspects of the disease, including the area and extent of depigmentation as well as the aesthetic impairment. The assessment is made on a numerical scale, categorizing different degrees of severity of facial vitiligo. The scale ranges from 0 to 4, with 0 corresponding to skin with no signs of vitiligo/complete repigmentation and 4 corresponding to very severe vitiligo.

The T-PhGVA is a global assessment of the disease across the entire body. It has the same numerical scale as the F-PhGVA, ranging from 0 to 4, with 0 corresponding to skin with no signs of vitiligo/complete repigmentation and 4 corresponding to very severe vitiligo.

Both scores are useful tools for evaluating the success of treatment for vitiligo on the face and the entire body and for documenting the progress of patients.

week 24 and 52
Change in disease stability
Prazo: week 24 and 52
The change of disease stability is defined as an exclusion of progressive vitiligo over a 1-year period with no increase in size of existing vitiligo foci, no new vitiligo foci, no Koebner phenomenon
week 24 and 52
Proportion of patient reported outcome: Dermatology Life Quality Index (DLQI)
Prazo: baseline, week 24 and 52
Dermatology Life Quality Index (DLQI): 10 questions, summing the score of each question resulting in a minimum of 0 and a maximum of 30 points
baseline, week 24 and 52
Proportion of patient reported outcome: Treatment Satisfaction Questionnaire for Medication (TSQM)
Prazo: baseline, week 24 and 52
Treatment Satisfaction Questionnaire for Medication (TSQM): questionnaire used to measure patient satisfaction with medication. The score ranges from 0 to 100 points
baseline, week 24 and 52
Proportion of patient reported outcome: Vitiligo Noticeability Scale (VNS)
Prazo: baseline, week 24 and 52
Vitiligo Noticeability Scale (VNS): score with a scale from one to five. One means more noticeable, five means no noticeability/visibility.
baseline, week 24 and 52
Proportion of patient reported outcome: Color-matching questions
Prazo: baseline, week 24 and 52
Color-matching questions: The patient assesses how well the color of the skin affected by VLD matches the surrounding, unaffected skin after treatment. Five answer options with a grading between "excellent" and "very poor" are possible.
baseline, week 24 and 52
Proportion of patient reported outcome: Facial Patient Global Impression of Change-Vitiligo (F-PaGIC-V)
Prazo: baseline, week 24 and 52
Facial Patient Global Impression of Change-Vitiligo (F-PaGIC-V): Patients assess the change in VLD on their face since starting treatment with the drug. Seven answer options are possible with a grading of "very much improved" and "very much worse"
baseline, week 24 and 52
Proportion of patient reported outcome: Total Body Patient Global Impression of Change-Vitiligo (T-PaGIC-V)
Prazo: baseline, week 24 and 52
Total Body Patient Global Impression of Change-Vitiligo (T-PaGIC-V): Patients assess the change of VLD on their total body since starting treatment with the drug. Seven answer options are possible with a grading of "very much improved" and "very much worse"
baseline, week 24 and 52
Proportion of patient reported outcome: Five Well-Being Index (WHO-5)
Prazo: baseline, week 24 and 52
Five Well-Being Index (WHO-5): a short self-reported measure of current mental wellbeing. It consists of five statements, which respondents rate according to a scale between 0 to 5
baseline, week 24 and 52
Proportion of patient reported outcome: Hospital Anxiety and Depression Scale (HADS)
Prazo: baseline, week 24 and 52
Hospital Anxiety and Depression Scale (HADS): is used to measure anxiety and depression in patients with physical illnesses. The severity of anxious and depressive symptoms during the past week is recorded by means of self-assessment on two subscales with seven items each. The total sum score can be used as a measure of general psychological impairment.
baseline, week 24 and 52
Proportion of patient reported outcome: Vitiligo Quality of Life Index (VitiQoL)
Prazo: baseline, week 24 and 52
Vitiligo Quality of Life Index (VitiQoL): specially developed instrument to measure the quality of life of people with vitiligo. It captures the psychosocial and emotional impact of the disease on the daily lives of those affected. As vitiligo can have not only physical but also significant psychological and social effects, the VitiQoL is a valuable tool to assess these comprehensively. Contains 16 questions.
baseline, week 24 and 52
Proportion of patient reported outcome: load thermometer
Prazo: baseline, week 24 and 52
The patient must indicate on a scale from zero to ten how much the VLD is bothering them. Grading from "not at all burdensome" to "extremely burdensome".
baseline, week 24 and 52

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Assessment of skin shave biopsies
Prazo: Baseline and week 52
Differences in the cutaneous immune microenvironment in skin shave biopsies will be investigated using multi-omics technics. Histology, immune-histology, multiplex and single-cell RNA sequencing analyses will be performed.
Baseline and week 52

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

25 de julho de 2024

Conclusão Primária (Real)

7 de julho de 2026

Conclusão do estudo (Estimado)

31 de agosto de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

31 de maio de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

20 de julho de 2026

Primeira postagem (Real)

24 de julho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

24 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

20 de julho de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever